Date | Time | Source | Headline | Symbol | Company |
26/02/2009 | 00:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/02/2009 | 00:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/02/2009 | 00:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/02/2009 | 00:44 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/02/2009 | 21:24 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/02/2009 | 21:49 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/02/2009 | 21:41 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/02/2009 | 17:54 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
10/02/2009 | 11:03 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 23:37 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 23:24 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 23:10 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 22:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 22:20 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 22:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/02/2009 | 16:30 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/02/2009 | 22:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/01/2009 | 03:00 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/01/2009 | 02:52 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/01/2009 | 16:59 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
09/12/2008 | 21:00 | Business Wire | Allos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
08/12/2008 | 18:15 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/12/2008 | 16:03 | Business Wire | Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
06/12/2008 | 17:30 | Business Wire | Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/12/2008 | 13:00 | Business Wire | Allos Therapeutics to Host Analyst and Investor Briefing on Monday, December 8, 2008 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/12/2008 | 21:05 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/12/2008 | 21:00 | Business Wire | U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/11/2008 | 21:05 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/11/2008 | 21:00 | Business Wire | U.S. FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Diffuse Large B-Cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
10/11/2008 | 22:09 | Edgar (US Regulatory) | Amended Current report filing (8-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |